Iron availability for erythropoiesis is controlled by the iron-regulatory hormone hepcidin. Increased erythropoiesis negatively regulates hepcidin synthesis by erythroferrone (ERFE), a hormone produced by erythroid precursors in response to erythropoietin (EPO). The mechanisms coordinating erythropoietic activity with iron homeostasis in erythrocytosis with low EPO are not well defined as exemplified by dominantly inherited (heterozygous) gain-of-function mutation of human EPO receptor (mtHEPOR) with low EPO characterized by postnatal erythrocytosis. We previously created a mouse model of this mtHEPOR that develops fetal erythrocytosis with a transient perinatal amelioration of erythrocytosis and its reappearance at 3-6 weeks of age. Prenatally and perinatally, mtHEPOR heterozygous and homozygous mice (differing in erythrocytosis severity) had increased Erfe transcripts, reduced hepcidin, and iron deficiency. Epo was transiently normal in the prenatal life; then decreased at postnatal day 7, and remained reduced in adulthood. Postnatally, hepcidin increased in mtHEPOR heterozygotes and homozygotes, accompanied by low Erfe induction and iron accumulation. With aging, the old, especially mtHEPOR homozygotes had a decline of erythropoiesis, myeloid expansion, and local bone marrow inflammatory stress. In addition, mtHEPOR erythrocytes had a reduced lifespan. This, together with reduced iron demand for erythropoiesis, due to its age-related attenuation, likely contributes to increased iron deposition in the aged mtHEPOR mice. In conclusion, the erythroid drive-mediated inhibition of hepcidin production in mtHEPOR mice in the prenatal/perinatal period is postnatally abrogated by increasing iron stores promoting hepcidin synthesis. The differences observed in studied characteristics between mtHEPOR heterozygotes and homozygotes suggest dose-dependent alterations of downstream EPOR stimulation.

Department of Biology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Division of Hematology and Hematologic Malignancies The University of Utah School of Medicine Salt Lake City Utah USA

Zobrazit více v PubMed

Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-1443.

Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41(4):482-487.

Ganz T, Nemeth E. Iron homeostasis in host defense and inflammation. Nat Rev Immunol. 2015;15(8):500-510.

Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.

Ganz T. Erythropoietic regulators of iron metabolism. Free Rad Biol Med. 2019;133:69-74.

Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood. 2015;126(17):2031-2037.

Coffey R, Jung G, Olivera JD, et al. Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice. Blood. 2022;139(3):439-451.

Prchal JT. Primary and secondary Erythrocytoses/polycythemias. In Kaushansky K, Lichtman MA, Prchal JT, Levi M, Burns LJ, Linch DC, eds. Williams Hematology, 10th ed. McGraw Hill; 2021: 941-960.

Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614-621.

Gordeuk VR, Miasnikova GY, Sergueeva AI, et al. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood. 2011;118(19):5278-5282.

Ruschitzka FT, Wenger RH, Stallmach T, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA. 2000;97(21):11609-11613.

Díaz V, Gammella E, Recalcati S, et al. Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice. Hepatology. 2013;58(6):2122-2132.

James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.

Prchal JT, Crist WM, Goldwasser E, Perrine G, Prchal JF. Autosomal dominant polycythemia. Blood. 1985;66(5):1208-1214.

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.

Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105-2116.

de la Chapelle A, Träskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci USA. 1993;90(10):4495-4499.

Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood. 1995;86(1):15-22.

Arcasoy MO, Harris KW, Forget BG. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp Hematol. 1999;27(1):63-74.

Huang LJ, Shen YM, Bulut GB. Advances in understanding the pathogenesis of primary familial and congenital polycythaemia. Br J Haematol. 2010;148(6):844-852.

Divoky V, Liu Z, Ryan TM, Prchal JF, Townes TM, Prchal JT. Mouse model of congenital polycythemia: homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci USA. 2001;98(3):986-991.

Divoky V, Song J, Horvathova M, et al. Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor. J Mol Med (Berl). 2016;94(5):597-608.

Horvathova M, Kapralova K, Zidova Z, Dolezal D, Pospisilova D, Divoky V. Erythropoietin-driven signaling ameliorates the survival defect of DMT1-mutant erythroid progenitors and erythroblasts. Haematologica. 2012;97(10):1480-1488.

Shammas FV, Engeset A. Glycogen content and PAS staining pattern of human megakaryocytes. Scand J Haematol. 1986;37(3):237-242.

Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a−/−5b−/− mice due to decreased survival of early erythroblasts. Blood. 2001;98(12):3261-3273.

Bogdanova A, Mihov D, Lutz H, Saam B, Gassmann M, Vogel J. Enhanced erythro-phagocytosis in polycythemic mice overexpressing erythropoietin. Blood. 2007;110(2):762-769.

Garcia-Santos D, Hamdi A, Saxova Z, et al. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model. Blood. 2018;131(2):236-246.

Akel A, Wagner CA, Kovacikova J, et al. Enhanced suicidal death of erythrocytes from gene-targeted mice lacking the cl-/HCO(3)(−) exchanger AE1. M J Physiol Cell Physiol. 2007;292(5):C1759-C1767.

Zidova Z, Kapralova K, Koralkova P, et al. DMT1-mutant erythrocytes have shortened life span, accelerated glycolysis and increased oxidative stress. Cell Physiol Biochem. 2014;34(6):2221-2231.

Zadrazil J, Horak P, Horcicka V, Zahalkova J, Strebl P, Hruby M. Endogenous erythropoietin levels and anemia in long-term renal transplant recipients. Kidney Blood Press Res. 2007;30(2):108-116.

Lucarelli G, Howard D, Stohlman F Jr. Regulation of erythropoiesis. XV. Neonatal erythropoiesis and the effect of nephrectomy. J Clin Invest. 1964;43(11):2195-2203.

Xavier-Ferrucio J, Scanlon V, Li X, et al. Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice. Blood. 2019;134(18):1547-1557.

Watowich SS, Xie X, Klingmuller U, et al. Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state. Blood. 1999;94(7):2530-2532.

Pasquier F, Marty C, Balligand T, et al. New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. Haematologica. 2018;103(4):575-586.

Kapralova K, Lanikova L, Lorenzo F, et al. RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood. 2014;123(3):391-394.

Montel-Hagen A, Blanc L, Boyer-Clavel M, et al. The Glut1 and Glut4 glucose transporters are differentially expressed during perinatal and postnatal erythropoiesis. Blood. 2008;112(12):4729-4738.

Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood. 2017;130(15):1693-1698.

Ho YH, Del Toro R, Rivera-Torres J, et al. Remodeling of bone marrow hematopoietic stem cell niches promotes myeloid cell expansion during premature or physiological aging. Cell Stem Cell. 2019;25(3):407-418.e6.

Roy A, Wang G, Iskander D, et al. Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development. Cell Rep. 2021;36(11):109698.

Zhao JL, Ma C, O'Connell RM, et al. Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell. 2014;14(4):445-459.

Cho RH, Sieburg HB, Muller-Sieburg CE. A new mechanism for the aging of hematopoietic stem cells: aging changes the clonal composition of the stem cell compartment but not individual stem cells. Blood. 2008;111(12):5553-5561.

Rekhtman N, Choe KS, Matushansky I, Murray S, Stopka T, Skoultchi AI. PU.1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiation. Mol Cell Biol. 2003;23(21):7460-7474.

Ganz T. Macrophages and systemic iron homeostasis. J Innate Immun. 2012;4(5-6):446-453.

Lee SJ, Park SY, Jung MY, Bae SM, Kim IS. Mechanism for phosphatidylserine-dependent erythrophagocytosis in mouse liver. Blood. 2011;117(19):5215-5223.

Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051-2054.

Mojzikova R, Koralkova P, Holub D, et al. Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios. Br J Haematol. 2014;165(4):556-563.

Sulovska L, Holub D, Zidova Z, et al. Characterization of iron metabolism and erythropoiesis in erythrocyte membrane defects and thalassemia traits. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(2):231-237.

Huang H, Constante M, Layoun A, Santos MM. Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood. 2009;113(15):3593-3599.

Suresh S, Rajvanshi PK, Noguchi CT. The many facets of erythropoietin physiologic and metabolic response. Front Physiol. 2020;10:1534.

Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101(41):14907-14912.

Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med. 2013;210(2):205-208.

Zhang YL, Radhakrishnan ML, Lu X, Gross AW, Tidor B, Lodish HF. Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex. Mol Cell. 2009;33(2):266-274.

Teng R, Gavrilova O, Suzuki N, et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun. 2011;2:520.

Valletta S, Thomas A, Meng Y, et al. Micro-environmental sensing by bone marrow stroma identifies IL-6 and TGFβ1 as regulators of hematopoietic ageing. Nat Commun. 2020;11(1):4075.

Huang X, Pierce LJ, Chen GL, Chang KT, Spangrude GJ, Prchal JT. Erythropoietin receptor signaling regulates both erythropoiesis and megakaryopoiesis in vivo. Blood Cells Mol Dis. 2010;44(1):1-6.

Lee S, Wong H, Castiglione M, Murphy M, Kaushansky K, Zhan H. JAK2V617F mutant megakaryocytes contribute to hematopoietic aging in a murine model of myeloproliferative neoplasm. Stem Cells. 2022;40(4):359-370.

McCranor BJ, Kim MJ, Cruz NM, et al. Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. Blood Cells Mol Dis. 2014;52(2-3):126-133.

Zermati Y, Fichelson S, Valensi F, et al. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol. 2000;28(8):885-894.

Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood. 1989;74(1):130-138.

Wang CQ, Udupa KB, Lipschitz DA. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol. 1995;162(1):134-138.

Forejtnikovà H, Vieillevoye M, Zermati Y, et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood. 2010;116(24):5357-5367.

Watowich SS. The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. J Invest Med. 2011;59(7):1067-1072.

Sulahian R, Cleaver O, Huang LJ. Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. Blood. 2009;113(21):5287-5297.

Chen GL, Chang K, Huang X, Spangrude GJ, Prchal JT. Erythropoietin signaling inhibits long term marrow reconstitution. Blood. 2006;108(11):912a Abstract 3194.

Divoky V, Prchal JT. Mouse surviving solely on human erythropoietin receptor (EpoR): model of human EpoR-linked disease. Blood. 2002;99(10):3873-3874.

Chang K, Pastore YD, Nussenzveig RH, Prchal JT. Erythropoietin signaling inhibits the short-term marrow reconstitution. Blood. 2005;106(11):848a Abstract 3028.

Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet. 2008;9:115-128.

Haas S, Trumpp A, Milsom MD. Causes and consequences of hematopoietic stem cell heterogeneity. Cell Stem Cell. 2018;22(5):627-638.

Zhang H, Wang S, Liu D, et al. EpoR-tdTomato-Cre mice enable identification of EpoR expression in subsets of tissue macrophages and hematopoietic cells. Blood. 2021;138(20):1986-1997.

Wang W, Liu W, Fidler T, et al. Macrophage inflammation, Erythrophagocytosis, and accelerated atherosclerosis in Jak2V617F mice. Circ Res. 2018;123(11):e35-e47.

Grisouard J, Li S, Kubovcakova L, et al. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016;128(6):839-851.

Wilkinson N, Pantopoulos K. IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2α mRNA translation. Blood. 2013;122(9):1658-1668.

Singh RP, Grinenko T, Ramasz B, et al. Hematopoietic stem cells but not multipotent progenitors drive erythropoiesis during chronic erythroid stress in EPO transgenic mice. Stem Cell Reports. 2018;10(6):1908-1919.

Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med. 2008;10:e36.

Li W, Wang Y, Zhao H, et al. Identification and transcriptome analysis of erythroblastic Island macrophages. Blood. 2019;134(5):480-491.

Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia. 2008;22(10):1828-1840.

Spivak JL. Polycythemia Vera. Curr Treat Options Oncol. 2018;19(2):12.

Gangaraju R, Song J, Kim SJ, et al. Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv. 2020;4(6):1115-1130.

Rives S, Pahl HL, Florensa L. Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica. 2007;92(5):674-677.

Al-Sheikh M, Mazurier E, Gardie B. A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene. Haematologica. 2008;93(7):1072-1075.

Rabadan Moraes G, Pasquier F, Marzac C, et al. An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms. Br J Haematol. 2022;198(1):131-136.